Literature DB >> 17457048

IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms.

Munenori Takaoka1, Seok-Hyun Kim, Takaomi Okawa, Carmen Z Michaylira, Douglas B Stairs, Cameron N Johnstone, Claudia D Andl, Ben Rhoades, James J Lee, Andres J P Klein-Szanto, Wafik S El-Deiry, Hiroshi Nakagawa.   

Abstract

Insulin-like growth factor binding protein (IGFBP)-3 exerts either proapoptotic or growth stimulatory effects depending upon the cellular context. IGFBP-3 is overexpressed frequently in esophageal cancer. Yet, the role of IGFBP-3 in esophageal tumor biology remains elusive. To delineate the functional consequences of IGFBP-3 overexpression, we stably transduced Ha-Ras(V12)-transformed human esophageal cells with either wild-type or mutant IGFBP-3, the latter incapable of binding Insulin-like growth factor (IGFs) as a result of substitution of amino-terminal Ile56, Leu80, and Leu81 residues with Glycine residues. Wild-type, but not mutant, IGFBP-3 prevented IGF-1 from activating the IGF-1 receptor and AKT, and suppressed anchorage-independent cell growth. When xenografted in nude mice, in vivo bioluminescence imaging demonstrated that wild-type, but not mutant IGFBP-3, abrogated tumor formation by the Ras-transformed cells with concurrent induction of apoptosis, implying a prosurvival effect of IGF in cancer cell adaptation to the microenvironment. Moreover, there was more aggressive tumor growth by mutant IGFBP-3 overexpressing cells than control cell tumors, without detectable caspase-3 cleavage in tumor tissues, indicating an IGF-independent growth stimulatory effect of mutant IGFBP-3. In aggregate, these data suggest that IGFBP-3 contributes to esophageal tumor development and progression through IGF-dependent and independent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17457048      PMCID: PMC2993006          DOI: 10.4161/cbt.6.4.3832

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  45 in total

1.  Mutation of three critical amino acids of the N-terminal domain of IGF-binding protein-3 essential for high affinity IGF binding.

Authors:  C K Buckway; E M Wilson; M Ahlsén; P Bang; Y Oh; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  2001-10       Impact factor: 5.958

2.  Insulin-like growth factor binding protein-3: insulin-like growth factor independence comes of age.

Authors:  Pinchas Cohen
Journal:  Endocrinology       Date:  2006-05       Impact factor: 4.736

Review 3.  Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities.

Authors:  R C Baxter
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-06       Impact factor: 4.310

Review 4.  P53 and IGFBP-3: apoptosis and cancer protection.

Authors:  A Grimberg
Journal:  Mol Genet Metab       Date:  2000-06       Impact factor: 4.797

5.  Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice.

Authors:  T Modric; J V Silha; Z Shi; Y Gui; A Suwanichkul; S K Durham; D R Powell; L J Murphy
Journal:  Endocrinology       Date:  2001-05       Impact factor: 4.736

Review 6.  IGF-I receptor signalling in transformation and differentiation.

Authors:  B Valentinis; R Baserga
Journal:  Mol Pathol       Date:  2001-06

Review 7.  Signalling pathways involved in antiproliferative effects of IGFBP-3: a review.

Authors:  R C Baxter
Journal:  Mol Pathol       Date:  2001-06

8.  Transfection of human insulin-like growth factor-binding protein 3 gene inhibits cell growth and tumorigenicity: a cell culture model for lung cancer.

Authors:  R Hochscheid; G Jaques; B Wegmann
Journal:  J Endocrinol       Date:  2000-09       Impact factor: 4.286

9.  Subtractive hybridization of mRNA from early passage and senescent endothelial cells.

Authors:  J Grillari; O Hohenwarter; R M Grabherr; H Katinger
Journal:  Exp Gerontol       Date:  2000-03       Impact factor: 4.032

10.  Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras.

Authors:  Seok-Hyun Kim; Hiroshi Nakagawa; Arunasalam Navaraj; Yoshio Naomoto; Andres J P Klein-Szanto; Anil K Rustgi; Wafik S El-Deiry
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

View more
  11 in total

1.  IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment.

Authors:  Mitsuteru Natsuizaka; Hideaki Kinugasa; Shingo Kagawa; Kelly A Whelan; Seiji Naganuma; Harry Subramanian; Sanders Chang; Kei J Nakagawa; Naryan L Rustgi; Yoshiaki Kita; Shoji Natsugoe; Devraj Basu; Phyllis A Gimotty; Andres J Klein-Szanto; J Alan Diehl; Hiroshi Nakagawa
Journal:  Am J Cancer Res       Date:  2014-01-15       Impact factor: 6.166

2.  Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells.

Authors:  Mitsuteru Natsuizaka; Shinya Ohashi; Gabrielle S Wong; Azal Ahmadi; Ross A Kalman; Daniela Budo; Andres J Klein-Szanto; Meenhard Herlyn; J Alan Diehl; Hiroshi Nakagawa
Journal:  Carcinogenesis       Date:  2010-05-31       Impact factor: 4.944

3.  A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors.

Authors:  Shinya Ohashi; Mitsuteru Natsuizaka; Seiji Naganuma; Shingo Kagawa; Sotai Kimura; Hiroshi Itoh; Ross A Kalman; Momo Nakagawa; Douglas S Darling; Devraj Basu; Phyllis A Gimotty; Andres J Klein-Szanto; J Alan Diehl; Meenhard Herlyn; Hiroshi Nakagawa
Journal:  Cancer Res       Date:  2011-09-02       Impact factor: 12.701

4.  Response to Different Oxygen Partial Pressures and Evolution Analysis of Apoptosis-Related Genes in Plateau Zokor (Myospalax baileyi).

Authors:  Zhifang An; Xiaoqi Chen; Jimei Li
Journal:  Front Genet       Date:  2022-06-08       Impact factor: 4.772

5.  Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.

Authors:  Marta Guix; Anthony C Faber; Shizhen Emily Wang; Maria Graciela Olivares; Youngchul Song; Sherman Qu; Cammie Rinehart; Brenda Seidel; Douglas Yee; Carlos L Arteaga; Jeffrey A Engelman
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

6.  Hypoxia activates the cyclooxygenase-2-prostaglandin E synthase axis.

Authors:  James J Lee; Mitsuteru Natsuizaka; Shinya Ohashi; Gabrielle S Wong; Munenori Takaoka; Carmen Z Michaylira; Daniela Budo; John W Tobias; Michiyuki Kanai; Yasuhiro Shirakawa; Yoshio Naomoto; Andres J P Klein-Szanto; Volker H Haase; Hiroshi Nakagawa
Journal:  Carcinogenesis       Date:  2009-12-30       Impact factor: 4.944

7.  Insulin-like growth factor binding protein-3 inhibits cell adhesion via suppression of integrin β4 expression.

Authors:  Hyo-Jong Lee; Ji-Sun Lee; Su Jung Hwang; Ho-Young Lee
Journal:  Oncotarget       Date:  2015-06-20

8.  NDRG1 overexpression promotes the progression of esophageal squamous cell carcinoma through modulating Wnt signaling pathway.

Authors:  Runna Ai; Yulin Sun; Zhimin Guo; Wei Wei; Lanping Zhou; Fang Liu; Denver T Hendricks; Yang Xu; Xiaohang Zhao
Journal:  Cancer Biol Ther       Date:  2016-07-14       Impact factor: 4.742

9.  Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.

Authors:  Jheri J Dupart; Jonathan C Trent; Ho-Young Lee; Kenneth R Hess; Andrew K Godwin; Takahiro Taguchi; Wei Zhang
Journal:  Mol Cancer       Date:  2009-11-10       Impact factor: 27.401

10.  Insulin-like growth factor-independent insulin-like growth factor binding protein 3 promotes cell migration and lymph node metastasis of oral squamous cell carcinoma cells by requirement of integrin β1.

Authors:  Yi-Chen Yen; Jenn-Ren Hsiao; Shih Sheng Jiang; Jeffrey S Chang; Ssu-Han Wang; Ying-Ying Shen; Chung-Hsing Chen; I-Shou Chang; Jang-Yang Chang; Ya-Wen Chen
Journal:  Oncotarget       Date:  2015-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.